Conference Presentation, Panel
Precision Medicine: Accelerating Treatments From Potential to Reality
Milken InstituteMike Milken, Margaret Anderson, Pradeep Khosla, Brian Drucker, Betsy Nabel, Sam Hoggud
- The average global life expectancy rose from 31 years in 1900 to 71 years over 114 years, a gain surpassing the 11-year increase achieved over 4 million years of prior human evolution.
- The convergence of big data, artificial intelligence, and digital health is creating a "golden age of medicine" characterized by precision medicine, immunology, and rapid data processing capabilities.
- Pradeep Khosla (UC San Diego) emphasized that the transistor and IT infrastructure are foundational to precision medicine, enabling "collisions of collaboration" between mathematicians, engineers, physicists, and clinicians to solve non-linear biological problems.
- The paradigm of medical research has shifted from vertical silos to horizontal, multi-sector teams, as exemplified by the development of Gleevec for chronic myeloid leukemia (CML).
- Brian Drucker (Oregon Health & Science University) noted that Gleevec was developed using a 25-year research timeline to identify a molecular target ("the lock"), resulting in a 100% response rate in Phase I trials and FDA approval within 2.5 years of clinical trial initiation.
- Sam Hogg (UCSF) argued that precision medicine requires a shift from paternalism to a partnership model where patients actively engage via digital health devices and mobile monitoring.
- Over 70% of individuals with life-threatening diseases express willingness to share personal genomic data to advance treatments, though concerns remain regarding data security, insurance discrimination, and the need for trust.
- Current federal funding for the NIH Precision Medicine Initiative ($215 million) is described by panelists as 100,000 to 1,000,000 times smaller than the capital required to fully realize the field's potential.
- Global competition in bioscience is intensifying, with China committing $1.9 trillion to its 12th Five-Year Plan, while the UK now hosts one in four of the world's top 20 bioscience universities.
- Private sector investment is replacing federal dominance in academic research; at Mass General Brigham, government funding dropped from 60-70% to 40%, with the remainder sourced from venture capital and pharma.
- A $500 million "Knight Challenge" at OHSU required a match from the state of Oregon ($200 million) and the private sector, illustrating the necessity of public-private-philanthropic co-investment to fill NIH funding gaps.
- The average age of a researcher receiving their first independent NIH grant is currently 42, a statistic panelists argue must be reduced to the low 30s to encourage early-career innovation, as most Nobel-winning ideas originate in the 20s and 30s.
- Sam Hogg proposed two specific priorities: establishing an institute for neuro-disorders and creating a multi-omics database (genomics, proteomics, metabolomics, microbiome) that is publicly accessible.
- The panel called for a new educational model to train physician-scientists in data science, noting that current medical curricula do not adequately prepare clinicians to interpret complex genomic and proteomic data.
- Brian Drucker advocated for an "Apollo Project" for biological diseases, leveraging current sequencing and AI technologies to compress drug development timelines from years to months.
- The cost of genome sequencing has dropped to the "thousand-dollar genome," but the field must advance to the level of protein cellular networks to identify new drug targets.
- Panelists warned that failure to invest in basic science and early-career researchers could allow the U.S. to lose its preeminence in biomedical research to international competitors like China and the UK.
- The economic impact of biomedical advancement is linked to "social capital," where communities hosting bioscience industries see higher educational outcomes and economic resilience.
- Mike Milken highlighted a historical pattern where the most powerful leaders could not save their own children from disease, yet modern technology could prevent such losses if financial and political will is mobilized immediately.
- The panelists urged the audience to engage intellectually and financially, framing precision medicine not as a threat to privacy but as a collective imperative to eliminate life-threatening diseases for future generations.